The company is focused on the clinical development and commercial exploitation through partnering of its highly innovative anti-infective portfolio and has an open door policy to discussing potential business relationships. These range from partnering and licensing through to investment and non-dilutive funding as well as risk sharing and joint ventures with industry, academia and governments.
Please contact us at firstname.lastname@example.org to start a discussion.
The company has already completed one collaboration with China Medical Systems signed in 2017 who have rights to the XF platform for Greater China and related territories.
- ID Week – 19-23 October 2022 14/07/2022